The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Check out the website , and hopefully they will take heed and do more investor awareness PR on what they are R working on not just for business leads but for general awareness /understanding them . So far they are on the right track after a long stint of silence. Quarter1 should be fantastic IMO
Has there ever been any research written on this company? Don't think the shop broker does health care.
It does seem as though there may something to salvage here and it could be something of a bargain on say a 2 year investment horizon. Be interested in any thoughts even to the contrary. The technology is hard to understand.
I bought some SUPP a few days ago ..mainly for the nanopore holding. That might be worth a look as well.
At the Company's AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement:
"Having closed 2020 with a strong final quarter and order book carried forward, we are pleased to report that the same pattern has continued during the first quarter of 2021. We expect further growth from the services business and TMT Pro™, assuming that the general economic background continues to return more to normality in the second half of 2021."
Looks good and itive to me
Rerrate coming. Some nice buys today and the sp is and has been steadily and slowly creeping up.
Any other bits of good or positive news and we should get the rerate.
Well done .. yes seems timing may be good and if we are the best in the uk/Europe/world , far ahead of most emerging companies then this company must look extremely promising as a prospective acquisition to future diagnostics and medicine development for precision diseases so really when people understand that then this should rerate .
...I have bought a few again. if it doesn't happen for these now, it never will!
I listened to it just now .. what I would say is the presentor and mariola sounded very professional , however Ian pike was lots of ums, errs and quite hurried in speech. I would say Ian’s strengths lie with technology , inventions & patents , but leadership and presentation needs to b clear simple and strong in tone and language.
In regards to proteome sciences dismissal of Twitter , I really think they have this all wrong . They are looking at it in terms of generating business contacts . Unfortunately I don’t use LinkedIn and this is more for connecting with professional in the industry all over , rather than PR awareness. Proteome sciences is getting better with more communication than that long period of silence we have had to endure but IMO they need to also create investor awareness and presence .. Twitter I would say is better than FB fir a companies presence . Twitter , is where the general person/investor resides and generates chatter/tweets /create awareness.
PR is vital for SP progression . It is not about business leads to be generated ; it is about investor communication where people build and support the company in its aim and strategy.
If you don’t have investors on board you lay there stagnant .. so the strategy should be communication at the core ; sight your dynamic vision , and who you are working with . Renew your look . Renew that dull website. Engage . I would be investing in a marketing PR manager / website Maintenance/ social media updates for the business who can build a persona and presence !!!! I hope you read this !
Listen to mariola and gain a perspective that we are well ahead of peers in this new dynamic evolving industry , that we provide a superior service of data chart and analysis of proteins and their interplays.. compared to our US competitors we are well underrated so in fact we would be a good target for acquisition /merger .. now finally we are re rating.
https://player.vimeo.com/video/536467083
Article in genome web by Adam bonislawski “As advances in technologies and workflows have sparked renewed interest in plasma proteomics, Proteome Sciences is positioning its TMTcalibrator product as a tool for plasma analysis.”
Someone is accumulating.
Yes compared to peers we are extremely undervalued .. with proteomics being recognised as the core science to progress precise medicine , it is the field that is forecast to outperform. It is our time to shine!
The level 2 order book is looking really positive now, PEEL are offering 7.25, then SINGER & Winterfloods are 7.50, SCAP & MREX are next at 8p. If buying continues to outweigh selling then there appears very little resistance.
The market cap here vs US listed peers such as Seer ($3b), Nautilus ($1.4b) and Quantum-Si ($1.4b) is nonsensical. It's also worth noting that in 2013 PRM hit a 74p off the back of their agreement with Thermo Fisher, which is still performing very well. They had 196m shares in issue then vs 295m today, but even so the valuation of £145m is 7x the current level...
With collaborations & strategic clarity promised in 2021, I really can't see too much downside from the current levels? Especially seeing as they are cash generative...
Looking good .. what a lovely day !
I wouldn’t worry about helium. They sell then buy back .
Multi year breakout of the 5p range is significant, backed up by the 900k director buy which is a material amount... I think this goes much higher, it appears materially undervalued vs peers.
Helium sells but then buys back in .. I wouldn’t give too much emphasis to them .
The interesting thing is whether this has taken out the last of the Helium holding.
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Roger McDowell, a Director of the Company, that on 16 April 2021 he purchased 900,000 Ordinary Shares in the Company at a price of 5.00p per share. Roger McDowell now holds 3,400,000 Ordinary Shares in the Company, which represents approximately 1.15% of the issued share capital of the Company.
Something going on; someone in the know .. proteomics now being discovered & invaluable to so many things in the biotech area .. hopefully some good news to come or this is being spied as an invaluable buy by the larger biotechs. Did u see thermofisher news acquiring ?
HYcol I don’t know if there is any connections there with proteome sciences ... they also have researchers there in Germany . I’m pointing out proteomics research’ and study on Covid . Please elaborate on your scientific methodology of proteomics research if you understand it in depth .
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Richard Dennis, Chief Commercial Officer, that on 12 April and 13 April 2021 he purchased, in aggregate, 625,000 Ordinary Shares in the Company at an average price of 5.22p per share. Richard Dennis now holds 625,000 Ordinary Shares in the Company, which represents approximately 0.21% of the issued share capital of the Company.
re previous post
The GenomeWeb article refers to research which has nothing at all related to Proteome Sciences technology .
The research did not use TMT isobaric label (DDA) it used non label methodology (DIA).
Lots have changed in this field and it’s a growing sector , at the core of everything now in the field of drug development and disease research and cures . 10 yrs proteomics was not a recognised area like
It is now .. i see it. It is integral to
Most things now and prms
Communication is going in-the right direction .. it’s up to you who and what u want to invest in .
They were saying that 10 years ago, AngelMarbles!
I have checked PRM's figures and, like other UK cos of this type, their IP is in the books at cost less depreciation, rather than what it might be worth to a competitor. Its small profit this year would have been larger if not for Covid but, I suspect, not by a multiplier. NAV in books is negative and that is clearly valuing the IP and contacts as well as ongoing research at Zero!
But a lot of water can flow under the bridge if you buy in hope of a quick bid - got that tee shirt!
Yes proteomics is the next big thing don’t ya know?